Thymic Cancer, Thymic Carcinoma, Thymic Epithelial Tumor
Conditions
Keywords
thymic malignancy, thymoma, chemotherapy, targeted therapy, immunotherapy, molecular landscape
Brief summary
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Interventions
DRUGChemotherapy
different treatments based on the molecular analysis
Sponsors
Shanghai Chest Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven diagnosis of thymic malignancies * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | 20 years | Collect detailed clinical information on patients with thymic malignancies via the electronic medical records |
| Disease control rate (DCR) | 20 years | Collect detailed clinical information on patients with thymic malignancies via the electronic medical records |
| Progression-free survival (PFS) | 20 years | Collect detailed clinical information on patients with thymic malignancies via the electronic medical records |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 20 years | Collect detailed clinical information on patients with thymic malignancies via the electronic medical records |
Countries
China
Outcome results
None listed